|
|
|
| Effect of Rdiotherapy combined with EGFR-TKI Targeting Therapy on Serum Tumor Markers and Therapeutic Effect in Patients with Stage Ⅳ Non-small Cell Lung Cancer |
| YANG Jiu, HONG Mei, LIU Zhiyuan, et al |
| Nanjing Brain Hospital, Jiangsu Nanjing 210029, China |
|
|
|
|
Abstract Objective: To explore the radiotherapy combined EGFR - TKI targeted therapy Ⅳ NSCLC serum tumor markers and therapeutic effect. Methods: From October 2017 to September 2018, 92 patients with stage Ⅳ NSCLC in our hospital were selected as the research objects. The treatment methods were divided into two groups, 46 cases in each group. The patients in each group were treated with radiotherapy alone and EGFR-TKI as the combined group. The clinical efficacy, serum biochemical indicators, immune function and toxic and side effects of the two groups were compared. Results: The total effective rate was 82.61% in the combined group, significantly higher than 54.35% in the radiotherapy group (χ2=8.51,P<0.05). Compared within the group, serum biochemical indexes of VEGF, CEA, CA125, MMP9 and CYFRA21-1 in the two groups were significantly decreased after treatment (all P＜0.05). After treatment, all biochemical indexes in the combined group were significantly lower than those in the radiotherapy group (P＜0.05). Immune function after treatment compared, CD4+ and NK level joint group were significantly higher than in radiotherapy group (P＜0.05). The CD8+ level was significantly lower than that of the radiotherapy group (P＜0.05). Conclusion: Radiotherapy combined with EGFR-TKI can improve the clinical therapeutic effect, effectively control tumor progression, improve immune function, and provide a better internal environment without increasing toxic and side effects.
|
|
|
|
|
|
[1] 赵振宙,靳宏星,楚琳,等.非小细胞肺癌表皮生长因子受体突变相关影像学进展[J].中国中西医结合影像学杂志,2018,16(4):434~436.
[2] Ricciuti B, Mencaroni C, Paglialunga L, et al. Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy[J]. Medical Oncology, 2016, 33(2):18.
[3] Ahn M J, Sun J M, Lee S H, et al. EGFR TKI combination with immunotherapy in non-small cell lung cancer[J]. Expert Opinion on Drug Safety, 2017, 16(4):465~469.
[4] 支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志,2016,37(7):433~436.
[5] Xie J, Zhang X. The impact of genomic profiling for novel cancer therapy-recent progress in non-small cell lung cancer[J]. Journal of Genetics & Genomics, 2016, 43(1):3~10.
[6] Ku E , Desai A Y , Fang D , et al. Toxicity profile in non-small cell lung cancer patients treated with lung stereotactic body radiation therapy using the modified dynamic conformal arc (MDCA) technique[J]. International Journal of Radiation Oncology Biology Physics, 2016, 96(2):E654.
[7] 孟菁菁,谷少杰,张琳,等.血清CA125、CEA、IL-10水平检测对晚期非小细胞肺癌患者预后价值分析[J].实用癌症杂志,2017,32(9):1438~1440.
[8] Lai I, Yang C A, Lin P C, et al. Long noncoding RNA MIAT promotes non-small cell lung cancer proliferation and metastasis through MMP9 activation[J]. Oncotarget, 2017, 8(58):98148~98162.
[9] 姚舒洋,支修益.非小细胞肺癌术后辅助EGFR-TKI的治疗进展[J].首都医科大学学报,2016,37(6):773~776.
[10] 陈体,苏雪娟.CT平扫图像中的胸膜标记预测非毗邻非小细胞肺癌对脏层胸膜侵犯的初步研究[J].中国中西医结合影像学杂志,2017,15(6):691~693,696. |
|
|
|
2020, Vol. 26 
